Transforming growth factor β-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 229-233

  Wang, Hui ^a   Wu, Junli ^b   Zhang, Ye ^a   Xue, Xiaofeng ^a   Tang, Dong ^a   Yuan, Zhongxu ^a   Chen, Minyong ^a   Wei, Jishu ^b   Zhang, Jingjing ^c   Miao, Yi ^b  

^a Laboratory of General Surgery   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Jiangsu Province Academy of Clinical Medicine Institute of Tumor Biology   (China)

Author keywords

Cancer stem like cell; Epithelial mesenchymal transition; Invasion; Migration; Pancreatic cancer; Transforming growth factor

Indexed keywords

BIOLOGICAL MARKER; CD24 ANTIGEN; CD44V ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL ACTIVITY; CELL CYCLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PHENOTYPE; UPREGULATION; WESTERN BLOTTING;

EID: 84855217170     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.448     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 78: 654-663, 1996.
3. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
4. Philip PA, Mooney M, Jaffe D, et al: Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27: 5660-5669, 2009.
5. Rosenberg L: Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine. Int J Pancreatol 22: 81-93, 1997.
6. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353, 1996.
7. Warshaw AL and Fernandez-del CC: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
8. Nakajima S, Doi R, Toyoda E, et al: N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10: 4125-4133, 2004.
9. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G and Gress TM: TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211, 2001.
10. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
11. Kang Y and Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279, 2004.
12. Thiery JP, Acloque H, Huang RY, et al: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
13. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
14. Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429-1437, 2009.
15. Kabashima A, Higuchi H, Takaishi H, et al: Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer 124: 2771-2779, 2009.
16. Ellenrieder V, Hendler SF, Boeck W, et al: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228, 2001.
17. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
18. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison S and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
19. Hermann P, Huber S, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
20. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
21. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
22. - progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60: 4403-4011, 2000.
23. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
24. Guzman ML, Swiderski CF, Howard DS, et al: Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99: 16220-16225, 2002.
25. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
26. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al: Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27: 2059-2068, 2009.
27. Truty MJ and Urrutia R: Basics of TGF-beta and pancreatic cancer. Pancreatology 7: 423-435, 2007.
28. Ito D, Fujimoto K, Doi R, et al: Chronic exposure of transforming growth factor beta 1 confers a more aggressive tumor phenotype through downregulation of p21(WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells. Surgery 136: 364-374, 2004.